Table 2.
SDHB immunohistochemistry test results according to subgroups within SDH-related and non-SDH-related tumours
| Number of tumours | SDHB immunohistochemistry negative | SDHB immunohistochemistry positive | Sensitivity (95% CI) | Specificity (95% CI) | |
|---|---|---|---|---|---|
| Retrospective | |||||
|
| |||||
| SDH-related | |||||
| SDHB | 34 | 34 | 0 | 100% (90–100) | ·· |
| SDHC | 4 | 4 | 0 | 100% (40–100) | ·· |
| SDHD | 38 | 38 | 0 | 100% (91–100) | ·· |
| Non-SDH related | |||||
| RET | 12 | 0 | 12 | ·· | 100% (74–100) |
| VHL | 24 | 0 | 24 | ·· | 100% (86–100) |
| NF3 | 29 | 0 | 29 | ·· | 100% (88–100) |
| Sporadic | 34 | 3 | 31 | ·· | 91% (76–98) |
|
| |||||
| Prospective | |||||
|
| |||||
| SDH-related | 26 | 26 | 0 | 100% (87–100) | ·· |
| Non-SDH related | 19 | 3 | 16 | ·· | 84% (60–97) |